- Home
- GLRE vs BVS Comparison
GLRE vs BVS Comparison
Compare GLRE & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- BVS
- Stock Information
- Founded
- GLRE 2004
- BVS 2011
- Country
- GLRE Cayman Islands
- BVS United States
- Employees
- GLRE N/A
- BVS N/A
- Industry
- GLRE Property-Casualty Insurers
- BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GLRE Finance
- BVS Health Care
- Exchange
- GLRE Nasdaq
- BVS Nasdaq
- Market Cap
- GLRE 466.5M
- BVS 496.7M
- IPO Year
- GLRE 2007
- BVS 2021
- Fundamental
- Price
- GLRE $14.44
- BVS $6.55
- Analyst Decision
- GLRE
- BVS Strong Buy
- Analyst Count
- GLRE 0
- BVS 4
- Target Price
- GLRE N/A
- BVS $15.00
- AVG Volume (30 Days)
- GLRE 95.2K
- BVS 515.1K
- Earning Date
- GLRE 05-07-2025
- BVS 05-06-2025
- Dividend Yield
- GLRE N/A
- BVS N/A
- EPS Growth
- GLRE N/A
- BVS N/A
- EPS
- GLRE 1.32
- BVS N/A
- Revenue
- GLRE $717,617,000.00
- BVS $567,699,000.00
- Revenue This Year
- GLRE N/A
- BVS N/A
- Revenue Next Year
- GLRE N/A
- BVS $6.11
- P/E Ratio
- GLRE $10.97
- BVS N/A
- Revenue Growth
- GLRE 2.79
- BVS 8.60
- 52 Week Low
- GLRE $11.95
- BVS $5.28
- 52 Week High
- GLRE $15.82
- BVS $14.38
- Technical
- Relative Strength Index (RSI)
- GLRE 71.34
- BVS 38.57
- Support Level
- GLRE $13.33
- BVS $6.47
- Resistance Level
- GLRE $14.65
- BVS $6.72
- Average True Range (ATR)
- GLRE 0.48
- BVS 0.29
- MACD
- GLRE 0.10
- BVS 0.06
- Stochastic Oscillator
- GLRE 86.36
- BVS 24.85
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.